Marc C. Smaldone, MD, MSHP, FACS
- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Research Profile
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Associate Professor, Department of Surgical Oncology
Kidney, Bladder, and Prostate Cancer TRDG Member
NCCN, Prostate Cancer Early Detection Panel Member
Specialties
Treatment Focus
- Robotic and laparoscopic minimally invasive surgery
- Continent urinary diversion
- Salvage and reconstructive Surgery
Research Program
Treatment Philosophy
I am a urologic oncologist specializing in the surgical management of tumors of the kidney, bladder, prostate, adrenal, testis and other genitourinary organs. As part of the multi-disciplinary Genitourinary Cancer Patient Care Team, I work closely with my colleagues in Medical and Radiation Oncology to develop a comprehensive treatment plan that offers the best chance for cure for each patient.
The mission at the Fox Chase Cancer Center is to deliver world class oncologic care in the most compassionate and respectful way possible. A cancer diagnosis brings fear and uncertainty for patients and their families, and my personal philosophy is to treat patients how I would wish for my family members to be treated. Patient education is essential, and I consider it of utmost importance to take the time necessary for patients to understand and feel comfortable with all possible treatment options to inspire confident decision making.
I have expertise in open, laparoscopic, and robotic surgical techniques, which allows me to tailor a specific treatment plan based on individual patient need and preferences. I have particular expertise in minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life, including nerve-sparing prostatectomy for patients with prostate cancer and partial nephrectomy for patients with kidney cancer. I have experience performing both robotic and open cystectomy for patients with bladder cancer, and prefer to construct continent urinary diversions whenever possible. I have a clinical interest in the surgical management of patients with high risk and advanced disease, and have experience performing retroperitoneal lymph node dissection following chemotherapy in patients with testicular cancer, cytoreductive nephrectomy and thrombectomy for patients with metastatic kidney cancer or tumors extending into the vena cava, and salvage surgery following radiation for patients with bladder or prostate cancer.
Follow on Twitter: @FCUroOnc
Educational Background
- Fellowship: Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
- Residency: Urologic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MS, Health Policy Research, University of Pennsylvania, Philadelphia, PA
- MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY
Certifications
- American Board of Urology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Prostate Cancer Early Detection Panel
- American Urological Association
- Society of Urologic Oncology
Bill Doyle
Bill Doyle
Bill Doyle always knew he wanted to be on the radio. As one half of the Deminski & Doyle talk radio show on New Jersey 101.5, life was good for Bill until he was diagnosed with bladder cancer at 52. After surgery and several rounds of chemotherapy, Bill is back on the airwaves, thanks in part to the support of his family and the countless 101.5 listeners who have offered words of support during his cancer journey.
John Mullarkey, Jr.
John Mullarkey, Jr.
I have always been proactive about my health and started having annual prostate exams when I turned 50 in 2007. My first report was great and showed that my PSA level was undetectable.
Debra Getz
Debra Getz
Debra underwent a successful right nephrectomy, IVC thrombectomy, adrenalectomy, and retroperitoneal lymph node dissection to treat her metastatic kidney cancer.
Sister Marcille McEntee
Sister Marcille McEntee
Her gastroenterologist performed a PET scan which revealed a rare kind of cancer, a mucosal melanoma. “At that point, my urologist admitted 'this is beyond me. You need to go somewhere else',” she recalled.
Chuck Leonard
Chuck Leonard
In August 2012, at the age of 61, Chuck Leonard was diagnosed with stage four kidney cancer that had metastasized to his lungs. After seeing one doctor, Chuck decided to seek a second opinion from a specialist at Fox Chase Cancer Center, where he planned to take part in a clinical trial. However, additional testing revealed he was a candidate for surgery. Chuck also underwent radiation using Cyberknife technology at Fox Chase Buckingham after an MRI revealed the kidney cancer had spread to his brain. “In 2016, I can mark three years since I have had detectable cancer,” he said. “I’m so thankful for all the outstanding care, both medical and other, provided by Fox Chase and the caring doctors and nurses. Hopefully, my tests will continue to have good outcomes, and, if not, I know I’m getting the best care possible from Fox Chase Cancer Center.”
Pages
Research Program
Research Interests
- Quality of care
- Comparative effectiveness
- Risk assessment
- Access disparities
- Surgical outcomes
- Health services research
Selected Publications
Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed
Goel N, Manstein SM, Ward WH, DeMora L, Smaldone MC, Farma JM, Uzzo RG, Esnaola NF. Does the Surgical Apgar Score predict serious complications after elective major cancer surgery? Journal of Surgical Research, 231:242-7, 2018.
Smaldone, M.C., Corcoran, A.T., Hayn M.H., Konety, B.R., Hrebinko Jr., R.L., Davies, B.J. (2009). Estimation of mortality and morbidity risk in patients undergoing radical cystectomy with continent diversion using the POSSUM and Portsmouth POSSUM predictor equations. J Urol,182(6): 2619-24. PubMed
Smaldone, M.C., Cowan, J., Carroll, P.R., Davies, B.J. (2010). Comparison of eligibility for active surveillance and pathologic outcomes in men undergoing radical prostatectomy in a large community-based cohort. J Urol,183(1):138-43. PubMed
Kutikov, A., Smaldone, M.C., Egleston, B.L., Manley, B.J., Simhan, J., Boorjian, S.A., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2011). Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephromety Score. Eur Urol, 60(2): 241-8. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B., Simhan, J., Canter, D.J., Teper, E., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2012). Assessing performance trends in laparoscopic nephrectomy and nephron sparing surgery for localized renal tumors. Urology, 80(2): 286-92. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B.L., Canter, D.J., Viterbo, R., Chen, D.Y., Jewett, M.A., Greenberg, R.E., Uzzo, R.G. (2012). Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 118(4):997-1006. PubMed
Smaldone, M.C., Egleston, B.L., Uzzo, R.G., Kutikov, A. (2012). Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol 188(6): 2089-94. PubMed
Kutikov, A., Egleston, B.L., Canter, D., Smaldone, M.C., Wong, Y.N., Uzzo, R.G. (2012). Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol, 188(6): 2077-83. PubMed
Smaldone, M.C., Simhan, J., Kutikov, A., Canter, D.J., Starkey, R., Zhu, F., Nielsen, M.E., Stitzenberg, K.B., Greenberg, R.E., Uzzo, R.G. (2013) Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urol Oncol, 31(8): 1663-9. PubMed
Tomaszewski, J.J., Uzzo, R.G., Handorf, E.A., Bekelman, J.E., Corcoran, A.T., Kutikov, A., Mehrazin, R., Smaldone, M.C. (2014) Care transitions between hospitals are associated with treatment delays for patients with muscle invasive bladder cancer. J Urol, 192(5): 1349-54. PubMed
Kim, S.P, Gross, C.P., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Karnes, R.J., Thompson, R.H., Hand, L.C., Yu, J.B., Trinh, Q.D., Ziegenfuss, J.Y., Sun, M., Tilburt, J.C. (2014) Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists. Med Care, 52(7):579-85. PubMed
Martin, J.M., Handorf, E.A., Kutikov, A., Uzzo, R.G., Bekelman, J.E., Horwitz, E.M., Smaldone, M.C. (2014) The rise and fall of prostate brachytherapy: Use of brachytherapy in the treatment of localized prostate cancer in the National Cancer Database. Cancer, 120(14):2114-21. PubMed
Corcoran, A.T., Handorf, E, Canter, D, Tomaszewski, J.J., Bekelman, J.E., Kim, S.P., Uzzo, R.G., Kutikov. A, Smaldone, M.C. (2015) Variation in performance of candidate surgical quality measures for muscle invasive bladder cancer by hospital type. BJU Int, 115(2):230-7. PubMed
Wang, E.H., Gross, C.P., Tilburt, J.C., Yu, J.B., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Abouassally, R., Sun, M., Kim, S.P. Shared decision making and use of decision AIDS for localized prostate cancer: perceptions from radiation oncologists and urologists. (2015) JAMA Intern Med, 175(5):792-9. PubMed
Additional Publications
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Associate Professor, Department of Surgical Oncology
Kidney, Bladder, and Prostate Cancer TRDG Member
NCCN, Prostate Cancer Early Detection Panel Member
Treatment Focus
- Robotic and laparoscopic minimally invasive surgery
- Continent urinary diversion
- Salvage and reconstructive Surgery
Research Program
Treatment Philosophy
I am a urologic oncologist specializing in the surgical management of tumors of the kidney, bladder, prostate, adrenal, testis and other genitourinary organs. As part of the multi-disciplinary Genitourinary Cancer Patient Care Team, I work closely with my colleagues in Medical and Radiation Oncology to develop a comprehensive treatment plan that offers the best chance for cure for each patient.
The mission at the Fox Chase Cancer Center is to deliver world class oncologic care in the most compassionate and respectful way possible. A cancer diagnosis brings fear and uncertainty for patients and their families, and my personal philosophy is to treat patients how I would wish for my family members to be treated. Patient education is essential, and I consider it of utmost importance to take the time necessary for patients to understand and feel comfortable with all possible treatment options to inspire confident decision making.
I have expertise in open, laparoscopic, and robotic surgical techniques, which allows me to tailor a specific treatment plan based on individual patient need and preferences. I have particular expertise in minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life, including nerve-sparing prostatectomy for patients with prostate cancer and partial nephrectomy for patients with kidney cancer. I have experience performing both robotic and open cystectomy for patients with bladder cancer, and prefer to construct continent urinary diversions whenever possible. I have a clinical interest in the surgical management of patients with high risk and advanced disease, and have experience performing retroperitoneal lymph node dissection following chemotherapy in patients with testicular cancer, cytoreductive nephrectomy and thrombectomy for patients with metastatic kidney cancer or tumors extending into the vena cava, and salvage surgery following radiation for patients with bladder or prostate cancer.
Follow on Twitter: @FCUroOnc
Education
Educational Background
- Fellowship: Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
- Residency: Urologic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MS, Health Policy Research, University of Pennsylvania, Philadelphia, PA
- MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY
Certifications
- American Board of Urology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Prostate Cancer Early Detection Panel
- American Urological Association
- Society of Urologic Oncology
Research Profile
Research Interests
- Quality of care
- Comparative effectiveness
- Risk assessment
- Access disparities
- Surgical outcomes
- Health services research
Publications
Selected Publications
Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed
Goel N, Manstein SM, Ward WH, DeMora L, Smaldone MC, Farma JM, Uzzo RG, Esnaola NF. Does the Surgical Apgar Score predict serious complications after elective major cancer surgery? Journal of Surgical Research, 231:242-7, 2018.
Smaldone, M.C., Corcoran, A.T., Hayn M.H., Konety, B.R., Hrebinko Jr., R.L., Davies, B.J. (2009). Estimation of mortality and morbidity risk in patients undergoing radical cystectomy with continent diversion using the POSSUM and Portsmouth POSSUM predictor equations. J Urol,182(6): 2619-24. PubMed
Smaldone, M.C., Cowan, J., Carroll, P.R., Davies, B.J. (2010). Comparison of eligibility for active surveillance and pathologic outcomes in men undergoing radical prostatectomy in a large community-based cohort. J Urol,183(1):138-43. PubMed
Kutikov, A., Smaldone, M.C., Egleston, B.L., Manley, B.J., Simhan, J., Boorjian, S.A., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2011). Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephromety Score. Eur Urol, 60(2): 241-8. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B., Simhan, J., Canter, D.J., Teper, E., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2012). Assessing performance trends in laparoscopic nephrectomy and nephron sparing surgery for localized renal tumors. Urology, 80(2): 286-92. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B.L., Canter, D.J., Viterbo, R., Chen, D.Y., Jewett, M.A., Greenberg, R.E., Uzzo, R.G. (2012). Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 118(4):997-1006. PubMed
Smaldone, M.C., Egleston, B.L., Uzzo, R.G., Kutikov, A. (2012). Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol 188(6): 2089-94. PubMed
Kutikov, A., Egleston, B.L., Canter, D., Smaldone, M.C., Wong, Y.N., Uzzo, R.G. (2012). Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol, 188(6): 2077-83. PubMed
Smaldone, M.C., Simhan, J., Kutikov, A., Canter, D.J., Starkey, R., Zhu, F., Nielsen, M.E., Stitzenberg, K.B., Greenberg, R.E., Uzzo, R.G. (2013) Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urol Oncol, 31(8): 1663-9. PubMed
Tomaszewski, J.J., Uzzo, R.G., Handorf, E.A., Bekelman, J.E., Corcoran, A.T., Kutikov, A., Mehrazin, R., Smaldone, M.C. (2014) Care transitions between hospitals are associated with treatment delays for patients with muscle invasive bladder cancer. J Urol, 192(5): 1349-54. PubMed
Kim, S.P, Gross, C.P., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Karnes, R.J., Thompson, R.H., Hand, L.C., Yu, J.B., Trinh, Q.D., Ziegenfuss, J.Y., Sun, M., Tilburt, J.C. (2014) Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists. Med Care, 52(7):579-85. PubMed
Martin, J.M., Handorf, E.A., Kutikov, A., Uzzo, R.G., Bekelman, J.E., Horwitz, E.M., Smaldone, M.C. (2014) The rise and fall of prostate brachytherapy: Use of brachytherapy in the treatment of localized prostate cancer in the National Cancer Database. Cancer, 120(14):2114-21. PubMed
Corcoran, A.T., Handorf, E, Canter, D, Tomaszewski, J.J., Bekelman, J.E., Kim, S.P., Uzzo, R.G., Kutikov. A, Smaldone, M.C. (2015) Variation in performance of candidate surgical quality measures for muscle invasive bladder cancer by hospital type. BJU Int, 115(2):230-7. PubMed
Wang, E.H., Gross, C.P., Tilburt, J.C., Yu, J.B., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Abouassally, R., Sun, M., Kim, S.P. Shared decision making and use of decision AIDS for localized prostate cancer: perceptions from radiation oncologists and urologists. (2015) JAMA Intern Med, 175(5):792-9. PubMed
Additional Publications
Related Articles
48 PATIENT COMMENTS
-
5.0
June 21, 2019
Dr. Smaldone has exuded confidence in himself and the procedure in tackling my situation. I in turn have had the utmost respect and confidence in him and his staff. His bedside manner is unequaled by any doctor I have had. I would recommend him on any given chance. Thank you Doc.
-
5.0
June 17, 2019
Great.
-
5.0
June 16, 2019
Very good.
-
5.0
June 13, 2019
Dr. Smaldone is one of the most caring, dedicated doctors I have had the privilege of dealing with.
-
5.0
May 22, 2019
Dr Marc Smaldone is the most caring, compassionate and quietly confident doctor I have ever gone to. I have recommended family members and friends to see him and they too were so pleased. He is truly the best!!
-
5.0
May 21, 2019
Dr Smaldone is an outstanding person and physician. I am alive and well today due to the guidance and medical mastery of Dr Smaldone before, during and after surgery. He takes time to explain things and is always there to answer any questions or concerns. I believe he is one of the very best in his field and have recommended him and FoxChase to several people .
-
5.0
May 15, 2019
Every visit has been handled professionally. No complaints.
-
5.0
May 14, 2019
Excellent care and professional provider and staff.
-
5.0
May 02, 2019
Marc Smaldone is a fantastic physician/surgeon who I would recommend to all without reservation.
-
5.0
May 02, 2019
Dr. Smaldone is a great doctor and even a better person. He is available 24/7, which says a lot because most doctors I have dealt with aren't as polite, kind and courteous as Dr. Smaldone.
-
5.0
April 22, 2019
Always a very nice experience, if you have to be here.
-
5.0
April 21, 2019
My experience with Dr. Smaldone and all Fox Chase staff has always been excellent. Dr. Smaldone and Fox Chase were definitely the best choice for my condition.
-
5.0
April 18, 2019
Dr. Smaldone & his staff are exceptional! Throughout all my experiences for the past five years at Fox Chase have been equally exceptional. - The level of expertise, kindness and truly caring attitude by all at Fox is truly praise worthy. THANK YOU ALL!
-
4.0
April 16, 2019
Excellent care [...].
-
5.0
April 16, 2019
This is a fabulous office. Dr. Smaldone is the best doctor I have ever had. Bar none.
-
5.0
April 15, 2019
Dr. Smaldone is a caring and excellent doctor. He always goes into the waiting room to speak to my wife and tell her how the visit had gone. We would go to no one else.
-
5.0
April 11, 2019
Could not be better !
-
5.0
April 06, 2019
Dr.Marc Smaldone and staff are wonderful
-
5.0
March 22, 2019
Dr. Smaldone is one of the most personable doctors I have ever encountered. I found him to be extremely professional, knowledgeable and most importantly caring. He makes himself available and it isn't just for "show." I like him a lot and Fox Chase is better for having him.
-
5.0
March 19, 2019
I would recommend this Dr. to anyone in need.
LOAD MORE